The European Agency for the Evaluation of Medicinal Products

London, 17 January 2002
Doc. Ref: EMEA/CPMP/4025/02

PRESS RELEASE

Committee for Proprietary Medicinal Products
Meeting of 15 to 17 January 2002

The CPMP adopted 4 opinions on initial marketing authorisation applications at this meeting:

- Positive opinions for the triple application **BolusacPlus** and **MicardisPlus** (telmisartan - hydrochlorothiazide) from Boehringer Ingelheim International GmbH, and **PritorPlus** (telmisartan - hydrochlorothiazide) from GlaxoSmithKline indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on telmisartan alone. Review by the EMEA began on 24 April 2001 and the opinion was adopted on 17 January 2002, with an active review time of 146 days.

- A positive opinion for **Invanz** (ertapenem) from Merck Sharp & Dohme indicated for the treatment of the following bacterial infections in adults: intra-abdominal infections, community acquired pneumonia and acute gynaecological infections. Review by the EMEA began on 26 December 2000 and the opinion was adopted on 17 January 2002, with an active review time of 211 days.

Summaries of opinions are available on the EMEA web site: http://www.emea.eu.int

A more detailed CPMP meeting report will be made available next week, including details from the MRFG meeting of 14 January 2002.

--ENDS--

For further information, please contact:

Martin Harvey,
EMEA press officer
Tel. (+44-20) 74 18 84 27, Mobile (+44-7768) 352312, E-mail: martin.harvey@emea.eu.int

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 09
E-mail: mail@emea.eu.int http://www.emea.eu.int